Target Price | $4.36 |
Price | $0.60 |
Potential |
625.59%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Nektar Therapeutics 2026 .
The average Nektar Therapeutics target price is $4.36.
This is
625.59%
register free of charge
$7.00
1,065.70%
register free of charge
$1.00
66.53%
register free of charge
|
|
A rating was issued by 9 analysts: 5 Analysts recommend Nektar Therapeutics to buy, 3 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Nektar Therapeutics stock has an average upside potential 2026 of
625.59%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 98.43 | 66.66 |
9.22% | 32.28% | |
EBITDA Margin | -130.78% | -216.44% |
9.06% | 65.50% | |
Net Margin | -109.47% | -175.40% |
63.38% | 60.22% |
10 Analysts have issued a sales forecast Nektar Therapeutics 2025 . The average Nektar Therapeutics sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Nektar Therapeutics EBITDA forecast 2025. The average Nektar Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Nektar Therapeutics Analysts have issued a net profit forecast 2025. The average Nektar Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.58 | -0.63 |
60.00% | 8.62% | |
P/E | negative | |
EV/Sales | 0.76 |
10 Analysts have issued a Nektar Therapeutics forecast for earnings per share. The average Nektar Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Nektar Therapeutics...
Analyst | Rating | Action | Date |
---|---|---|---|
Oppenheimer |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
B. Riley Securities |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 04 2024 |
Analyst Rating | Date |
---|---|
Locked
Oppenheimer:
Locked
➜
Locked
|
Mar 14 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 25 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 13 2025 |
Locked
B. Riley Securities:
Locked
➜
Locked
|
Jan 08 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 04 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.